Logo image of RVAC

RIVERVIEW ACQUISITION CORP-A (RVAC) Stock Fundamental Analysis

NASDAQ:RVAC - Nasdaq - US7693951045 - Common Stock - Currency: USD

11.15  -0.31 (-2.71%)

After market: 11.18 +0.03 (+0.27%)

Fundamental Rating

2

Taking everything into account, RVAC scores 2 out of 10 in our fundamental rating. RVAC was compared to 0 industry peers in the Unkown industry. While RVAC seems to be doing ok healthwise, there are quite some concerns on its profitability. RVAC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RVAC has reported negative net income.
RVAC Yearly Net Income VS EBIT VS OCF VS FCFRVAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 0 2M 4M

1.2 Ratios

Industry RankSector Rank
ROA -1.87%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RVAC Yearly ROA, ROE, ROICRVAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 0 0.5 1 1.5 2

1.3 Margins

RVAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVAC Yearly Profit, Operating, Gross MarginsRVAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

6

2. Health

2.1 Basic Checks

RVAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
RVAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RVAC Yearly Shares OutstandingRVAC Yearly Shares OutstandingYearly Shares Outstanding 2021 10M 20M 30M
RVAC Yearly Total Debt VS Total AssetsRVAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 50M 100M 150M 200M 250M

2.2 Solvency

RVAC has an Altman-Z score of 6.74. This indicates that RVAC is financially healthy and has little risk of bankruptcy at the moment.
RVAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.74
ROIC/WACCN/A
WACC9.06%
RVAC Yearly LT Debt VS Equity VS FCFRVAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 50M 100M 150M 200M

2.3 Liquidity

RVAC has a Current Ratio of 5.20. This indicates that RVAC is financially healthy and has no problem in meeting its short term obligations.
RVAC has a Quick Ratio of 5.20. This indicates that RVAC is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 5.2
Quick Ratio 5.2
RVAC Yearly Current Assets VS Current LiabilitesRVAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 500K 1M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18126280.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RVAC will show a very strong growth in Earnings Per Share. The EPS will grow by 45.99% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.5%
EPS Next 2Y29.9%
EPS Next 3Y40.21%
EPS Next 5Y45.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVAC Yearly Revenue VS EstimatesRVAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
RVAC Yearly EPS VS EstimatesRVAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RVAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
RVAC is valuated quite expensively with a Price/Forward Earnings ratio of 36.44.
RVAC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.70.
Industry RankSector Rank
PE N/A
Fwd PE 36.44
RVAC Price Earnings VS Forward Price EarningsRVAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVAC Per share dataRVAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RVAC's earnings are expected to grow with 40.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.9%
EPS Next 3Y40.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVAC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIVERVIEW ACQUISITION CORP-A

NASDAQ:RVAC (8/26/2022, 8:01:18 PM)

After market: 11.18 +0.03 (+0.27%)

11.15

-0.31 (-2.71%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.07%
Inst Owner Change0%
Ins Owners19.27%
Ins Owner Change0%
Market Cap348.44M
Analysts82.5
Price Target14.79 (32.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 36.44
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.57
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)0.31
Fwd EY2.74%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS7.08
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.2
Quick Ratio 5.2
Altman-Z 6.74
F-Score4
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18126280.33%
EPS Next Y12.5%
EPS Next 2Y29.9%
EPS Next 3Y40.21%
EPS Next 5Y45.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A